外科肿瘤学
乳腺癌
医学
BRCA2蛋白
肿瘤科
癌症
内科学
突变
病理
种系突变
生物
基因
遗传学
作者
Hannaleena Eerola,Päivi Heikkilä,Anitta Tamminen,Kristiina Aittomäki,Carl Blomqvist,Heli Nevanlinna
摘要
Abstract Introduction Histopathological features of BRCA1 and BRCA2 tumours have previously been characterised and compared with unselected breast tumours; however, familial non- BRCA1/2 tumours are less well known. The aim of this study was to characterise familial non- BRCA1/2 tumours and to evaluate routine immunohistochemical and pathological markers that could help us to further distinguish families carrying BRCA1/2 mutations from other breast cancer families. Methods Breast cancer tissue specimens ( n = 262) from 25 BRCA1 , 20 BRCA2 and 74 non- BRCA1/2 families were studied on a tumour tissue microarray. Immunohistochemical staining of oestrogen receptor (ER), progesterone receptor (PgR) and p53 as well as the histology and grade of these three groups were compared with each other and with the respective information on 862 unselected control patients from the archives of the Pathology Department of Helsinki University Central Hospital. Immunohistochemical staining of erbB2 was also performed among familial cases. Results BRCA1 -associated cancers were diagnosed younger and were more ER-negative and PgR-negative, p53-positive and of higher grade than the other tumours. However, in multivariate analysis the independent factors compared with non- BRCA1/2 tumours were age, grade and PgR negativity. BRCA2 cases did not have such distinctive features compared with non- BRCA1/2 tumours or with unselected control tumours. Familial cases without BRCA1/2 mutations had tumours of lower grade than the other groups. Conclusions BRCA1 families differed from mutation-negative families by age, grade and PgR status, whereas ER status was not an independent marker.
科研通智能强力驱动
Strongly Powered by AbleSci AI